The compound, NP16, inhibits the MRSA-produced staphyloxanthin, which can resist the human immune system. This allows the body to overcome MRSA and mitigate it.
For the study, researchers examined the effects of NP16 in infected mice. They found the use of MP16 caused MRSA bacteria levels to fall by a factor of 10 within a few days. Additionally, they found the compound was not toxic to human cells.
The researchers claim this is the first study to use chemical genetics to treat MRSA, and they are now looking to see if similar approaches could help fight other superbugs, such as drug-resistant E. coli, according to the report.
More articles on healthcare quality:
Researchers develop diagnostic tool for Parkinson’s detection
5 things to know about clinical nurse specialists
CDC activates Emergency Operations Center for Harvey response
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
